Asa Elmore | Sutro Biopharma, Inc.

22nd Annual Federation of Clinical Immunology Societies (FOCIS) Meeting 2022– Abstract and Poster Presentation

22nd Annual Federation of Clinical Immunology Societies (FOCIS) Meeting 2022– Abstract and Poster Presentation Abstract Poster Presentation Th42 – Next-generation Immunostimulatory Antibody-drug Conjugate (iADC) Combines Direct Tumor Killing and Innate Immune...

JMP Securities Life Sciences Conference – Presentation

Events, News, Presentations

JMP Securities Life Sciences Conference – Presentation Webcast...

Jefferies Healthcare Conference 2022 – Presentation

Events, News, Presentations

Jefferies Healthcare Conference 2022 – Presentation Webcast...

2022 ASCO Annual Meeting – Abstract

Events, News, Presentations

2022 ASCO Annual Meeting – Abstract Download Abstract Number TPS5622 STRO-002-GM2: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination with Bevacizumab in...

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

News, Press Releases

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., June 3, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...